ABOUT ALETHIA BIOTHERAPEUTICS Alethia Biotherapeutics is a Montréal-based clinical-stage oncology biotech. Our lead asset, sotevtamab (AB-16B5), is a monoclonal antibody targeting tumor resistance mechanisms, notably epithelial-to-mesenchymal transition (EMT), thereby enabling existing immunotherapies to become significantly more
At Meridian our aspiration is to integrate our purpose into everything we do for people, the planet, and communities. We believe that our greatest opportunity is to create opportunity and meet people where they are. As